Literature DB >> 22426494

Overexpression of HGF attenuates the degeneration of Purkinje cells and Bergmann glia in a knockin mouse model of spinocerebellar ataxia type 7.

Satsuki Noma1, Wakana Ohya-Shimada, Masaaki Kanai, Keiji Ueda, Toshikazu Nakamura, Hiroshi Funakoshi.   

Abstract

Spinocerebellar ataxia type 7 (SCA7) is an autosomal dominant disorder associated with cerebellar neurodegeneration caused by expansion of a CAG repeat in the ataxin-7 gene. Hepatocyte growth factor (HGF), a pleiotrophic growth factor, displays highly potent neurotrophic activities on cerebellar neurons. A mutant c-met/HGF receptor knockin mouse model has revealed a role for HGF in the postnatal development of the cerebellum. The present study was designed to elucidate the effect of HGF on cerebellar neurodegeneration in a knockin mouse model of SCA7 (SCA7-KI mouse). SCA7-KI mice were crossed with transgenic mice overexpressing HGF (HGF-Tg mice) to produce SCA7-KI/HGF-Tg mice that were used to examine the phenotypic differences following HGF overexpression. The Purkinje cellular degeneration is thought to occur via cell-autonomous and non-cell autonomous mechanisms mediated by a reduction of glutamate transporter levels in Bergmann glia. The Purkinje cellular degeneration and reduced expression of glutamate transporters in the cerebellum of SCA7-KI mice were largely attenuated in the SCA7-KI/HGF-Tg mice. Moreover, phenotypic impairments exhibited by SCA7-KI mice during rotarod tests were alleviated in SCA7-KI/HGF-Tg mice. The bifunctional nature of HGF on both Purkinje cells and Bergmann glia highlight the potential therapeutic utility of this molecule for the treatment of SCA7 and related disorders.
Copyright © 2012 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22426494     DOI: 10.1016/j.neures.2012.03.001

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  7 in total

1.  Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7.

Authors:  Pavitra S Ramachandran; Ryan L Boudreau; Kellie A Schaefer; Albert R La Spada; Beverly L Davidson
Journal:  Mol Ther       Date:  2014-06-16       Impact factor: 11.454

Review 2.  Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.

Authors:  Pawel M Switonski; Wojciech J Szlachcic; Agnieszka Gabka; Wlodzimierz J Krzyzosiak; Maciej Figiel
Journal:  Mol Neurobiol       Date:  2012-09-04       Impact factor: 5.590

Review 3.  HGF-Met Pathway in Regeneration and Drug Discovery.

Authors:  Kunio Matsumoto; Hiroshi Funakoshi; Hisaaki Takahashi; Katsuya Sakai
Journal:  Biomedicines       Date:  2014-10-31

Review 4.  Mouse models of polyglutamine diseases: review and data table. Part I.

Authors:  Maciej Figiel; Wojciech J Szlachcic; Pawel M Switonski; Agnieszka Gabka; Wlodzimierz J Krzyzosiak
Journal:  Mol Neurobiol       Date:  2012-09-07       Impact factor: 5.590

Review 5.  Bergmann Glia, Long-Term Depression, and Autism Spectrum Disorder.

Authors:  Adrian Andrzej Chrobak; Zbigniew Soltys
Journal:  Mol Neurobiol       Date:  2016-01-26       Impact factor: 5.590

6.  Altered Secretome and ROS Production in Olfactory Mucosa Stem Cells Derived from Friedreich's Ataxia Patients.

Authors:  Sara Pérez-Luz; Frida Loria; Yurika Katsu-Jiménez; Daniel Oberdoerfer; Oscar-Li Yang; Filip Lim; José Luis Muñoz-Blanco; Javier Díaz-Nido
Journal:  Int J Mol Sci       Date:  2020-09-11       Impact factor: 5.923

7.  Respiratory dysfunction in a mouse model of spinocerebellar ataxia type 7.

Authors:  Anna F Fusco; Logan A Pucci; Pawel M Switonski; Debolina D Biswas; Angela L McCall; Amanda F Kahn; Justin S Dhindsa; Laura M Strickland; Albert R La Spada; Mai K ElMallah
Journal:  Dis Model Mech       Date:  2021-07-20       Impact factor: 5.758

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.